Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: Case example nifedipine immediate release formulation

Journal of Pharmaceutical Sciences

Volumn 102, Issue 9, 2013, Pages 3205-3219

  Wagner, Christian ^a   Thelen, Kirstin ^b   Willmann, Stefan ^b   Selen, Arzu ^c   Dressman, Jennifer B ^a  

^a GOETHE UNIVERSITY   (Germany)

^b BAYER AG   (Germany)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Absorption; Bioavailability; Computational ADME; Cytochrome P450; Dissolution; Drug metabolizing enzymes; First pass metabolism; Pharmacokinetics; Quality by design (QbD)

Indexed keywords

CYTOCHROME P450 3A; NIFEDIPINE;

ARTICLE; COMPUTER MODEL; COMPUTER PROGRAM; CROSSOVER PROCEDURE; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG SOLUBILITY; ENZYME INHIBITION; FIRST PASS EFFECT; GRAPEFRUIT JUICE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; INGESTION; NORMAL HUMAN; PHARMACOKINETICS; PLASMA; SMALL INTESTINE; STOMACH; STOMACH EMPTYING; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; BIOAVAILABILITY; COMPUTATIONAL ADME; CYTOCHROME P450; DISSOLUTION; DRUG METABOLIZING ENZYMES; FIRST-PASS METABOLISM; PHARMACOKINETICS; QUALITY BY DESIGN (QBD);

BEVERAGES; CALCIUM CHANNEL BLOCKERS; CITRUS PARADISI; COMPUTER SIMULATION; CYTOCHROME P-450 CYP3A; FOOD-DRUG INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; NIFEDIPINE; SOLUBILITY;

EID: 84881610739     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23611     Document Type: Article

References (80)

1. Dressman JB, Thelen K, Jantratid E. 2008. Towards quantitative prediction of oral drug absorption. Clin Pharmacokinet 47(10):655-667.
2. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. 2006. The human intestinal cytochrome P450 "pie". Drug Metab Dispos 34(5):880-886.
3. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS. 1999. Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 27(7):804-809.
4. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB. 1994. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 22(6):947-955.
5. Bailey DG, Arnold JM, Spence JD. 1994. Grapefruit juice and drugs. How significant is the interaction? Clin Pharmacokinet 26(2):91-98.
6. Bailey DG, Malcolm J, Arnold O, Spence JD. 1998. Grapefruit juice-drug interactions. Br J Clin Pharmacol 46(2):101-110.
7. Bailey DG, Spence JD, Munoz C, Arnold JM. 1991. Interaction of citrus juices with felodipine and nifedipine. Lancet 337(8736):268-269.
8. Kane GC, Lipsky JJ. 2000. Drug-grapefruit juice interactions. Mayo Clin Proc 75(9):933-942.
9. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB. 1997. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 99(10):2545-2553.
10. Lundahl J, Regardh CG, Edgar B, Johnsson G. 1995. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol 49(1-2):61-67.
11. Odou P, Ferrari N, Barthelemy C, Brique S, Lhermitte M, Vincent A, Libersa C, Robert H. 2005. Grapefruit juice-nifedipine interaction: Possible involvement of several mechanisms. J Clin Pharm Ther 30(2):153-158.
12. Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG, George CF. 1995. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 40(1):51-58.
13. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB. 1997. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 25(11):1228-1233.
14. Sica DA. 2006. Interaction of grapefruit juice and calcium channel blockers. Am J Hypertens 19(7):768-773.
15. Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A. 1994. Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation. Pharmazie 49(7):522-524.
16. Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS. 1997. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 52(4):311-315.
17. Spence JD. 1997. Drug interactions with grapefruit: Whose responsibility is it to warn the public? Clin Pharmacol Ther 61(4):395-400.
18. Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S. 1995. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 58(1):20-28.
19. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. 1995. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 58(2):127-131.
20. Ducharme MP, Warbasse LH, Edwards DJ. 1995. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 57(5):485-491.
21. Yee GC, Stanley DL, Pessa LJ, Dalla Costa T, Beltz SE, Ruiz J, Lowenthal DT. 1995. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 345(8955):955-956.
22. Lilja JJ, Kivisto KT, Neuvonen PJ. 1999. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 66(2):118-127.
23. James JS. 1995. Grapefruit juice and saquinavir. AIDS Treat News (no 235):5-6.
24. Miniscalco A, Lundahl J, Regardh CG, Edgar B, Eriksson UG. 1992. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J Pharmacol Exp Ther 261(3):1195-1199.
25. Paine MF, Widmer WW, Hart HL, Pusek SN, Beavers KL, Criss AB, Brown SS, Thomas BF, Watkins PB. 2006. A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr 83(5):1097-1105.
26. Grass GM, Sinko PJ. 2002. Physiologically based pharmacokinetic simulation modelling. Adv Drug Deliv Rev 54(3):433-451.
27. Juenemann D, Jantratid E, Wagner C, Reppas C, Vertzoni M, Dressman JB. 2011. Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles. Eur J Pharm Biopharm 77(2):257-264.
28. Keldenich J. 2009. Measurement and prediction of oral absorption. Chem Biodivers 6(11):2000-2013.
29. Kesisoglou F, Wu Y. 2008. Understanding the effect of API properties on bioavailability through absorption modeling. AAPS J 10(4):516-525.
30. Kuentz M, Nick S, Parrott N, Rothlisberger D. 2006. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur J Pharm Sci 27(1):91-99.
31. Okumu A, DiMaso M, Lobenberg R. 2009. Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products. Eur J Pharm Biopharm 72(1):91-98.
32. Parrott N, Lave T. 2002. Prediction of intestinal absorption: Comparative assessment of GASTROPLUS and IDEA. Eur J Pharm Sci 17(1-2):51-61.
33. Parrott N, Lukacova V, Fraczkiewicz G, Bolger MB. 2009. Predicting pharmacokinetics of drugs using physiologically based modeling-Application to food effects. AAPS J 11(1):45-53.
34. Shono Y, Jantratid E, Janssen N, Kesisoglou F, Mao Y, Vertzoni M, Reppas C, Dressman JB. 2009. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur J Pharm Biopharm 73(1):107-114.
35. Thelen K, Jantratid E, Dressman JB, Lippert J, Willmann S. 2010. Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing. J Pharm Sci 99(6):2899-2904.
36. Wagner C, Jantratid E, Kesisoglou F, Vertzoni M, Reppas C, Dressman JB. 2012. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model. Eur J Pharm Biopharm 82(1):127-138.
37. Willmann S, Edington AN, Kleine-Besten M, Jantratid E, Thelen K, Dressman JB. 2009. Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: Inter-individual variability of cimetidine absorption. J Pharm Pharmacol 61(7):891-899.
38. Willmann S, Thelen K, Becker C, Dressman JB, Lippert J. 2010. Mechanism-based prediction of particle size-dependent dissolution and absorption: Cilostazol pharmacokinetics in dogs. Eur J Pharm Biopharm 76(1):83-94.
39. Zhang X, Lionberger RA, Davit BM, Yu LX. 2011. Utility of physiologically based absorption modeling in implementing quality by design in drug development. AAPS J 13(1):59-71.
40. Foster TS, Hamann SR, Richards VR, Bryant PJ, Graves DA, McAllister RG. 1983. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J Clin Pharmacol 23(4):161-170.
41. Imai Y, Abe K, Sasaki S, Nihei M, Sekino H, Yoshinaga K. 1986. Pharmacokinetics and pharmacodynamics of conventional and slow release forms of nifedipine in essential hypertensive patients. Tohoku J Exp Med 148(4):421-438.
42. Kleinbloesem CH, van Brummelen P, Faber H, Danhof M, Vermeulen NP, Breimer DD. 1984. Variability in nifedipine pharmacokinetics and dynamics: A new oxidation polymorphism in man. Biochem Pharmacol 33(22):3721-3724.
43. Kleinbloesem CH, van Brummelen P, van de Linde JA, Voogd PJ, Breimer DD. 1984. Nifedipine: Kinetics and dynamics in healthy subjects. Clin Pharmacol Ther 35(6):742-749.
44. McAllister RG, Jr. 1982. Clinical pharmacokinetics of calcium channel antagonists. J Cardiovasc Pharmacol 4(Suppl 3):S340-S345.
45. Renwick AG, Robertson DR, Macklin B, Challenor V, Waller DG, George CF. 1988. The pharmacokinetics of oral nifedipine-A population study. Br J Clin Pharmacol 25(6):701-708.
46. Robertson DR, Waller DG, Renwick AG, George CF. 1988. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol 25(3):297-305.
47. Waller DG, Renwick AG, Gruchy BS, George CF. 1984. The first pass metabolism of nifedipine in man. Br J Clin Pharmacol 18(6):951-954.
48. German prescribers information. Accessed November, 2012, at: www.fachinfo.de.
49. Bode H, Brendel E, Ahr G, Fuhr U, Harder S, Staib AH. 1996. Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine. Eur J Clin Pharmacol 50(3):195-201.
50. Eichelbaum M. 1980. Clinical pharmacokinetics of calcium ion antagonists. Clin Invest Med 3(1-2):13-17.
51. Raemsch KD, Sommer J. 1983. Pharmacokinetics and metabolism of nifedipine. Hypertension 5(4 Pt 2):II18-24.
52. Kates RE. 1983. Calcium antagonists. Pharmacokinetic properties. Drugs 25(2):113-124.
53. Pasanisi F, Meredith PA, Reid JL. 1985. Pharmacokinetics of nifedipine. Int J Clin Pharmacol Res 5(1):63-66.
54. Reitberg DP, Love SJ, Quercia GT, Zinny MA. 1987. Effect of food on nifedipine pharmacokinetics. Clin Pharmacol Ther 42(1):72-75.
55. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12(3):413-420.
56. Jantratid E, Janssen N, Reppas C, Dressman JB. 2008. Dissolution media simulating conditions in the proximal human gastrointestinal tract: An update. Pharm Res 25(7):1663-1676.
57. Vertzoni M, Dressman J, Butler J, Hempenstall J, Reppas C. 2005. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur J Pharm Biopharm 60(3):413-417.
58. Glomme A, Marz J, Dressman JB. 2005. Comparison of a miniaturized shake-flask solubility method with automated potentiometric acid/base titrations and calculated solubilities. J Pharm Sci 94(1):1-16.
59. Klein S, Shah VP. 2008. A standardized mini paddle apparatus as an alternative to the standard paddle. AAPS PharmSciTech 9(4):1179-1184.
60. The United States Pharmacopeial Convention. 2008. The United States Pharmacopeia 31. Rockeville, Maryland.
61. Thelen K, Coboeken K, Willmann S, Burghaus R, Dressman JB, Lippert J. 2011. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: Oral solutions. J Pharm Sci 100(12):5324-5345.
62. Thelen K, Coboeken K, Willmann S, Dressman JB, Lippert J. 2012. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: Extension to describe performance of solid dosage forms. J Pharm Sci 101(3):1267-1280.
63. Willmann S, Lippert J, Schmitt W. 2005. From physicochemistry to absorption and distribution: Predictive mechanistic modelling and computational tools. Expert Opin Drug Metab Toxicol 1(1):159-168.
64. Willmann S, Schmitt W, Keldenich J, Dressman JB. 2003. A physiologic model for simulating gastrointestinal flow and drug absorption in rats. Pharm Res 20(11):1766-1771.
65. Willmann S, Schmitt W, Keldenich J, Lippert J, Dressman JB. 2004. A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 47(16):4022-4031.
66. Valentin J. 2002. Basic anatomical and physiological data for use in radiological protection: Reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals 2002. ICRP Publication 89. Ann ICRP 32(3-4):5-265.
67. Willmann S, Hohn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. 2007. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 34(3):401-431.
68. Willmann S, Lippert J, Sevestre M, Solodenko J, Fois F, Schmitt W. 2003. PK-Sim(R): A physiologically based pharmacokinetic "whole-body" model. Biosilico 1(4):121-124.
69. Kelly JG, O'Malley K. 1992. Clinical pharmacokinetics of calcium antagonists. An update. Clin Pharmacokinet 22(6):416-433.
70. Kleinbloesem CH, van Brummelen P, Breimer DD. 1987. Nifedipine. Relationship between pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 12(1):12-29.
71. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. 2004. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 1(1):85-96.
72. Galetin A, Houston JB. 2006. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: Impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 318(3):1220-1229.
73. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. 1997. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283(3):1552-1562.
74. Berger T. 1969. Studies on the gastric emptying mechanism in healthy persons and patients after partial gastrectomy. Acta Chir Scand Suppl 404:1-51.
75. Heading RC, Tothill P, Laidlaw AJ, Shearman DJ. 1971. An evaluation of indium DTPA chelate in the measurement of gastric emptying by scintiscanning. Gut 12(8):611-615.
76. Petring OU, Adelhoj B, Ibsen M, Poulsen HE. 1986. The relationship between gastric emptying of semisolids and paracetamol absorption. Br J Clin Pharmacol 22(6):659-662.
77. Petring OU, Flachs H. 1990. Inter- and intrasubject variability of gastric emptying in healthy volunteers measured by scintigraphy and paracetamol absorption. Br J Clin Pharmacol 29(6):703-708.
78. Marston SA, Polli JE. 1997. Evaluation of direct curve comparison metrics applied to pharmacokinetic profiles and relative bioavailability and bioequivalence. Pharm Res 14(10):1363-1369.
79. Challenor V, Waller DG, Gruchy BS, Renwick AG, George CF, McMurdo ET, McEwen J. 1986. The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine. Br J Clin Pharmacol 22(5):565-570.
80. Lin JH, Chiba M, Baillie TA. 1999. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51(2):135-158.